We are live on ! Find out more
CURX

Curanex Pharmaceuticals

10 hedge funds and large institutions have $206K invested in Curanex Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.03% more ownership

Funds ownership: 0%1.03% (+1%)

Holders
10
Holders Change
+10
Holders Change %
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
1
UBS Group
Switzerland
$46.5K +$292K +64,516 New
Citadel Advisors
2
Citadel Advisors
Florida
$46.1K +$290K +64,067 New
Jane Street
3
Jane Street
New York
$25.4K +$160K +35,277 New
TSS
4
Two Sigma Securities
New York
$23.4K +$147K +32,435 New
JF
5
Jump Financial
Illinois
$19.6K +$123K +27,200 New
Millennium Management
6
Millennium Management
New York
$13.8K +$86.7K +19,154 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$13.4K +$84.5K +18,670 New
SRL
8
Scientech Research LLC
New Jersey
$10.4K +$65.5K +14,480 New
Osaic Holdings
9
Osaic Holdings
Arizona
$4.45K +$25.8K +5,700 New
Barclays
10
Barclays
United Kingdom
$3.31K +$20.8K +4,594 New

CURX Hedge Fund Activity: Q3 2025 in Review

10 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q3 2025, worth a combined $206K.

Buyers outnumbered sellers: 10 funds opened new CURX positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $292K.

  • 10 institutional investors held Curanex Pharmaceuticals (CURX) as of Q3 2025, up from 0 in Q2 2025.
  • Funds reported $206K of Curanex Pharmaceuticals stock for Q3 2025.
  • 10 funds opened new Curanex Pharmaceuticals positions in Q3 2025 and 0 closed out, a net change of +10 holders.
  • The largest Curanex Pharmaceuticals buyer in Q3 2025 was UBS Group, an estimated $292K added.

Based on aggregated 13F filings for Q3 2025.